SOSV SF portfolio company, Prolific Machines, which is transforming biomanufacturing with light-controlled, AI-optimized biotherapeutics, has raised an initial $50 million in a Series B2 financing led by Atoms & Bits and Nant Capital. The funding brings the company’s total funding to more than $100 million.
Prolific Machines plans to use the capital to expand its platform across programs with pharmaceutical and biotechnology companies, increase staffing, and advance technology development and scale-up. Planned applications include biologics, biosimilars, and viral vectors, with early-stage work also planned for tissue and organ fabrication.
Did you know?
Picture this: Acres of cotton all around you. 150,000 plants. Now, harvest them all, collect the seeds — all 45 million of them — and start sequencing genomes.
Bruce Donald, Marcel Frenkel and Mark Hallen are analyzing over 19,290,123 compounds per second at quantum accuracies to develop drugs to previously incurable cancers.
Funded with $57 million from DCVC, Lowercarbon Capital and SOSV, among others, unspun aims to eliminate 1% of global carbon emissions
While it might look like a plant-based food company, NotCo is in the data and AI business—and aims to disrupt R&D in many industries that use animal and plant ingredients.
Gilberto Loureiro grew up inspecting fabrics in a Portuguese textile factory. With Smartex, he and co-founders Antonio Rocha and Paulo Ribeiro are eliminating textile defects—and their enormous cost both to manufacturers and the environment.
Miranda Wang and Jeanny Yao have an uncanny talent for finding value where others see waste. Their plastics upcycling company, Novoloop, just raised an $21m Series A to prove it.
To find the future of food, you may have to look no further than Emeryville, CA, a small city by the San Francisco Bay, where Upside Foods has built a 53,000-square-foot production facility for cultivated meat, the first of its kind.
In a timeless dilemma for new parents, Radhika and her husband Bharath discovered early that their baby daughter was a fussy sleeper. The situation left them tired and frustrated; being effective at work became a challenge.
In December 2021 Prellis raised a $14.5 million Series B and has signed partnerships with pharmaceutical behemoths including Bristol Myers Squibb and Sanofi.
It was 2016, and Chiu Chau was on the ropes. He had pitched nearly 150 venture capital firms. No one would invest. Everyone doubted the startup with the open-source laboratory robot.
Adebayo (“Ade”) Alonge and Amy Kao, co-founders of RxAll had nvented a handheld scanner for detecting counterfeit prescription drugs—an illicit, multibillion-dollar industry that kills an estimated 1 million people annually globally and 100,000 in Africa.